Mark Leuchtenberger

Mark Wayne Leuchtenberger was the founder of Mercator Therapeutics, Inc. (2009), holding the title of Director from 2009 to 2012.
Mr. Leuchtenberger is also the founder of Albor Biologics, Inc., Alvos Therapeutics, Inc. Mr. Leuchtenberger is currently the Chief Executive Officer at Spybiotech Ltd. since 2022, the Chairman at Neurosense Therapeutics Ltd. since 2021, and the Director at Wake Forest University.
Former positions include Chairman, President & Chief Executive Officer at Acusphere, Inc. from 2013 to 2015, President, Chief Executive Officer & Director at Chiasma, Inc. from 2015 to 2016, President & Chief Executive Officer at Targanta Therapeutics Corp.
from 2006 to 2009, President, Chief Executive Officer & Director at Melinta Subsidiary Corp.
from 2011 to 2013, President & Chief Executive Officer at Therion Biologics Corp.
from 2002 to 2006, President & Chief Executive Officer at Eterna Therapeutics LLC from 2018 to 2019, Chief Executive Officer at Ernexa Therapeutics, Inc. from 2017 to 2019, President, Chief Executive Officer & Director at IRX Therapeutics, Inc. from 2017 to 2019, Non-Executive Chairman at Xenetic Biosciences, Inc. from 2014 to 2015, Executive Chairman at Aleta Biotherapeutics, Inc., Director at EPIX Pharmaceuticals, Inc., Director at NeuroHealing Pharmaceuticals, Inc., Director at Beth Israel Deaconess Medical Center, Inc., and Director at Massachusetts Biotechnology Council.
Education includes an undergraduate degree from Wake Forest University and an MBA from Yale School of Management.